RxDoctor Payments Data

Theodore Brisson, MD

Urology · North Charleston, SCNPI 1699759563

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 716 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among urology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,743in general payments, 2019–2025

Across 716 payments — averaging $30.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Teleflex LLC$2K
  • Boston Scientific$2K
  • Axonics, Inc.$2K
  • Neotract Inc.$2K
  • Astellas Pharma US Inc$1K
  • plus $10K from 54 others

What the payments were for

  • Travel & lodging$1,0085%
  • Food & beverage$20,59595%
  • Education$1401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast62$3,251
Teleflex LLC22$1,917
Boston Scientific30$1,914
Axonics, Inc.65$1,754
Neotract Inc.19$1,513
Astellas Pharma US Inc68$1,416
Pfizer38$875
Sumitomo Pharma America, Inc.45$738
Johnson & Johnson26$598
Myriad Genetic Laboratories, Inc.13$552
AbbVie(2 entities)37$546
Endo Pharmaceuticals Inc.28$539
Antares Pharma, Inc.32$493
Caldera Medical, Inc2$446
Bayer15$381
Merck19$371
Procept Biorobotics Corporation10$356
Urovant Sciences Inc15$266
Urogen Pharma, Inc.11$241
Blue Earth Diagnostics10$225
Rochester Medical Corporation12$196
Dornier Medtech America, Inc1$182
Smith+Nephew8$181
C. R. Bard, Inc. & Subsidiaries15$180
Dendreon Pharmaceuticals LLC6$170
Ferring Pharmaceuticals Inc.6$148
Olympus America Inc.6$133
Tolmar, Inc.5$126
Sanofi1$121
Clarus Therapeutics Inc.7$115
AstraZeneca5$100
Novartis5$99
Medtronic5$97
Convatec Inc.3$91
Scynexis, Inc.4$87
Laborie Medical Technologies Corp.2$84
Tolmar Pharmaceuticals, Inc.4$79
Alnylam Pharmaceuticals Inc.3$75
Kowa Pharmaceuticals America, Inc.4$69
Angiodynamics, Inc.1$61
Integra Lifesciences Corporation1$60
Bioprotect Medical, Inc.2$59
Abbott3$58
Metuchen Pharmaceuticals4$53
Therapeuticsmd, Inc.3$49
Verity Pharmaceuticals Inc.2$49
Acerus Pharmaceuticals Corporation3$49
Histosonics, Inc.1$47
KARL Storz Endoscopy-america1$45
Myovant Sciences Inc.3$44
Ambu Inc.2$43
Conmed Corporation1$39
ABC Home Medical Supply, Inc.2$38
Halozyme Inc2$32
Avadel Specialty Pharmaceuticals, LLC2$31
Immunitybio, Inc.1$29
Intuitive Surgical2$28
Innovation Technologies Inc1$23
Progenics Pharmaceuticals, Inc.1$22
Palette Life Sciences, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,743 in reported general payments places this provider in the 90th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$968,177
Medicare patients
2,106
Services billed
14,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide47$665,817
MyrbetriqMirabegron468$319,876
GemtesaVibegron336$257,512
OrgovyxRelugolix30$78,056
Mirabegron ErMirabegron59$27,776
Solifenacin Succinate396$14,676
Tamsulosin Hcl1,028$13,597
Finasteride746$8,714
Estradiol113$8,129
PremarinEstrogens, Conjugated15$6,529
Tadalafil124$5,966
Methenamine Hippurate69$4,755
Desmopressin Acetate33$3,135
Trospium Chloride ErTrospium Chloride18$2,660
Testosterone Cypionate75$2,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,416$985,693515 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$738$335,568366 claims
PfizerPremarin$875$6,52915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 196 urology providers in South Carolina.

Other urology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →